https://www.nuaxia.com/blogRSS for NodeThu, 23 Jul 2026 10:15:20 GMThttps://www.nuaxia.com/pt/post/uk-biotech-financing-hits-five-year-high-as-venture-capital-momentum-accelerates-76a61e83e9adc08ae7890843fThu, 23 Jul 2026 10:11:08 GMTnuaxiahttps://www.nuaxia.com/ja/post/uk-biotech-financing-hits-five-year-high-as-venture-capital-momentum-accelerates-66a61e838a35450685a61ffb1Thu, 23 Jul 2026 10:11:06 GMTnuaxiahttps://www.nuaxia.com/it/post/uk-biotech-financing-hits-five-year-high-as-venture-capital-momentum-accelerates-56a61e8337ea166f54a50293fThu, 23 Jul 2026 10:11:04 GMTnuaxiahttps://www.nuaxia.com/fr/post/uk-biotech-financing-hits-five-year-high-as-venture-capital-momentum-accelerates-46a61e82d9adc08ae78908427Thu, 23 Jul 2026 10:11:00 GMTnuaxiahttps://www.nuaxia.com/es/post/uk-biotech-financing-hits-five-year-high-as-venture-capital-momentum-accelerates-36a61e828742bce731abfeadeThu, 23 Jul 2026 10:10:58 GMTnuaxiahttps://www.nuaxia.com/de/post/uk-biotech-financing-hits-five-year-high-as-venture-capital-momentum-accelerates-26a61e8224aad8f47a4068692Thu, 23 Jul 2026 10:10:56 GMTnuaxiahttps://www.nuaxia.com/zh/post/uk-biotech-financing-hits-five-year-high-as-venture-capital-momentum-accelerates-16a61e8444aad8f47a40686b4Thu, 23 Jul 2026 10:09:37 GMTnuaxiahttps://www.nuaxia.com/pt/post/fda-approves-lipfendra-as-the-first-oral-pcsk9-inhibitor-for-high-cholesterol-76a61e61f3b734a97bdc41ca3Thu, 23 Jul 2026 10:01:36 GMTnuaxiahttps://www.nuaxia.com/ja/post/fda-approves-lipfendra-as-the-first-oral-pcsk9-inhibitor-for-high-cholesterol-66a61e619943bedd9a4a5024eThu, 23 Jul 2026 10:01:34 GMTnuaxiahttps://www.nuaxia.com/it/post/fda-approves-lipfendra-as-the-first-oral-pcsk9-inhibitor-for-high-cholesterol-56a61e6149adc08ae789081ebThu, 23 Jul 2026 10:01:31 GMTnuaxiahttps://www.nuaxia.com/fr/post/fda-approves-lipfendra-as-the-first-oral-pcsk9-inhibitor-for-high-cholesterol-46a61e60eedd1a32780002eecThu, 23 Jul 2026 10:01:29 GMTnuaxiahttps://www.nuaxia.com/de/post/fda-approves-lipfendra-as-the-first-oral-pcsk9-inhibitor-for-high-cholesterol-36a61e5ed7ea166f54a5026dfThu, 23 Jul 2026 10:01:27 GMTnuaxiahttps://www.nuaxia.com/zh/post/fda-approves-lipfendra-as-the-first-oral-pcsk9-inhibitor-for-high-cholesterol-26a61e625a35450685a61fd95Thu, 23 Jul 2026 10:00:26 GMTnuaxiahttps://www.nuaxia.com/es/post/fda-approves-lipfendra-as-the-first-oral-pcsk9-inhibitor-for-high-cholesterol-16a61e5f65e93dcf6acf10037Thu, 23 Jul 2026 09:59:22 GMTnuaxiahttps://www.nuaxia.com/pt/post/lupin-licenses-two-oncology-programmes-to-kaveri-therapeutics-for-an-82-2-equity-stake-76a61e588edd1a32780002e70Thu, 23 Jul 2026 09:58:33 GMTnuaxiahttps://www.nuaxia.com/ja/post/lupin-licenses-two-oncology-programmes-to-kaveri-therapeutics-for-an-82-2-equity-stake-66a61e1cd9adc08ae78907de3Thu, 23 Jul 2026 09:57:57 GMTnuaxiahttps://www.nuaxia.com/it/post/lupin-licenses-two-oncology-programmes-to-kaveri-therapeutics-for-an-82-2-equity-stake-56a61e1bd9adc08ae78907dcfThu, 23 Jul 2026 09:57:52 GMTnuaxiahttps://www.nuaxia.com/fr/post/lupin-licenses-two-oncology-programmes-to-kaveri-therapeutics-for-an-82-2-equity-stake-46a61e1aea35450685a61f977Thu, 23 Jul 2026 09:57:50 GMTnuaxiahttps://www.nuaxia.com/zh/post/lupin-licenses-two-oncology-programmes-to-kaveri-therapeutics-for-an-82-2-equity-stake-36a61e593497e17ca11c7a10cThu, 23 Jul 2026 09:57:48 GMTnuaxiahttps://www.nuaxia.com/es/post/fda-grants-orphan-drug-designation-to-aftx-201-for-bag3-associated-dilated-cardiomyopathy-76a61e22f5e93dcf6acf0fcebThu, 23 Jul 2026 09:47:03 GMTnuaxia